The Parliamentary Health Committee this week will face its first (of a long list) "investigative" topic, taking the Medical Research Agency under the magnifying glass. An agency against which, already at the stage of legislative work in 2019, the then opposition had numerous objections, and subsequent years have confirmed the validity of at least some of them.
The decision to dismiss ABM CEO Radoslaw Sierpinski came as no surprise, as did its consequence, namely the notification to the prosecutor's office of the possibility of committing a crime, i.e. certifying untruths in competition documents. But that's just the tip of things to be clarified - and straightened out. Starting with the proverbial "byzantium" (ABM spends about 8 percent of its budget on its functioning, which puts it in the absolute vanguard of public institution...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
